MyFinsight
Home
Blog
About
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$213,503
Unit: Dollar
Positive Cash Flow Breakdown
Maturities of short-term investm...
Accounts payable, accrued expens...
Stock-based compensation expense
Cash proceeds from the issuance ...
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Net income (loss)
Net amortization of investment d...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net income (loss)
-5,313,300
4,623,049
-3,437,601
-5,078,498
Stock-based compensation expense
1,428,451
-2,040,793
1,099,210
2,634,563
Net amortization of investment discounts and premiums
708,011
799,634
-
-
Other current assets
213,822
-506,960
107,242
586,757
In-process research and development accrued expenses
0
-3,000,000
0
3,000,000
Accounts payable, accrued expenses and other current liabilities
1,559,244
63,326
355,101
-705,565
Operating lease right-of-use assets and liabilities, net
0
-4,405
0
4,430
Net cash provided by (used in) operating activities
-3,247,437
5,357,313
-2,090,532
-6,740,687
Purchase of short-term investments
47,584,528
31,972,991
5,726,027
3,138,534
Maturities of short-term investments
51,700,000
27,654,000
3,600,000
4,000,000
Net cash provided by (used in) investing activities
4,115,472
-4,318,991
-2,126,027
861,466
Cash proceeds from the sales of common stock under a capital on demandtm sales agreement
-
-
0
0
Taxes paid related to net share settlement of vested restricted stock units
654,964
-634,044
381,563
452,684
Cash proceeds from the issuance of stock upon exercise of stock options
7,575
-20,371
214
20,157
Net proceeds from issuance of common stock and concurrent issuance of pre-funded warrants upon public offering, net of offering costs
-
-
127,772,915
-
Repurchase of common stock
-
-
34,999,957
-
Net cash provided by (used in) financing activities
-647,389
-92,159,285
92,391,609
-432,527
Effect of exchange rate and valuation changes on cash equivalents
-7,142
-29,399
376
-2,605
Net increase (decrease) in cash and cash equivalents
213,503
-91,150,360
88,175,424
-6,314,353
Cash and cash equivalents at beginning of period
127,677,360
127,677,360
45,816,289
-
Cash and cash equivalents at end of period
52,757,766
52,544,263
127,677,360
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of short-term
investments
$51,700,000
(1192.50%↑ Y/Y)
Net cash provided by
(used in) investing...
$4,115,472
(377.73%↑ Y/Y)
Canceled cashflow
$47,584,528
Net increase
(decrease) in cash and cash...
$213,503
(103.38%↑ Y/Y)
Canceled cashflow
$3,901,968
Purchase of short-term
investments
$47,584,528
(1416.14%↑ Y/Y)
Accounts payable,
accrued expenses and...
$1,559,244
(320.99%↑ Y/Y)
Stock-based compensation
expense
$1,428,451
(-45.78%↓ Y/Y)
Cash proceeds from
the issuance of...
$7,575
(-62.42%↓ Y/Y)
Net cash provided by
(used in) operating...
-$3,247,437
(51.82%↑ Y/Y)
Net cash provided by
(used in) financing...
-$647,389
(-49.68%↓ Y/Y)
Effect of exchange rate
and valuation...
-$7,142
(-174.17%↓ Y/Y)
Canceled cashflow
$2,987,695
Canceled cashflow
$7,575
Net income (loss)
-$5,313,300
(-4.62%↓ Y/Y)
Taxes paid related to
net share...
$654,964
(44.68%↑ Y/Y)
Net amortization of
investment discounts and...
$708,011
Other current assets
$213,822
(-63.56%↓ Y/Y)
Buy us a coffee